News

PBS YouTube Video:

https://www.youtube.com/watch?v=FGaJ58p4cos&t=48s

RSS Feed:

Biotech, Pharmaceutical and Clinical Research News | BioSpace RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)

Captor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical Captor Therapeutics S.A. reports its financial results for the third quarter of 2022 and provides a business update. Aptorum Announces Publication of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG) Regulatory News: Aptorum Group Limited is pleased to announce the recent publication of a joint effort for the validated analytical method developed for the determination of plasma pro-EGCG and its metabolites after oral administration using ultra performance liquid chromatography coupled to quadrupole time of flight mass spectrometry. New study on deep learning technology for improving MRI image quality published in European Radiology SwiftMR™, an AI-powered MRI reconstruction solution from AIRS Medical proved its performance for enhancing the image quality of 3D high-resolution MRI. Kaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) – INVESTOR UPDATE Kaplan Fox & Kilsheimer LLP is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics Nordic Nanovector ASA has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics (“APIM”). Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update Can-Fite BioPharma Ltd. today announced financial results for the quarter ended September 30, 2022. Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection Spectrum Pharmaceuticals, Inc. today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations. CHUV, CERN and THERYQ join forces for a world first in cancer radiotherapy The Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, the European Laboratory for Particle Physics and THERYQ have signed an agreement for the world-first development of a revolutionary FLASH radiotherapy device that will use very high energy electron radiation to treat cancers resistant to conventional treatments. Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System inQB8 Medical Technologies, LLC, in Partnership with Peijia Medical Limited, announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrential Tricuspid Regurgitation. Final data from the AGENT study confirms topline results Isofol Medical AB, announced that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Liminal BioSciences Announces Holding of Special Meeting of Shareholders Liminal BioSciences Inc. announced that it will be holding a virtual special meeting of shareholders on January 20th, 2023. Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022 Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Neurophet, to participate in the Radiological Society of North America RSNA 2022 Neurophet, an artificial intelligence (AI) solution company for brain disease, announced on the 25th that Neurophet would participate in the Radiological Society of North America 2022 (RSNA 2022). Venus Medtech to showcase its structural heart treatments at London Valves 2022 Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The company will present its products at the conference taking place at the ExCeL London November 27-29, 2022 in its booth (#25), during a symposium, and at the official launch of the TARGET multicenter clinical study. RadNet, Inc. to Present at the BofA Securities 2022 Leveraged Finance Conference on November 29, 2022 RadNet, Inc. today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2022 Leveraged Finance Conference in Boca Raton, FL on Tuesday, November 29, 2022 at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time). Mednow to Host Quarterly Conference Call on Tuesday November 29, 2022, at 8:30am EST on its Fourth-Quarter 2022 Financial Results
on November 25, 2022 at 12:00 am
In a volatile year, marked with challenges, BioSpace is taking a pause to reflect on the many “wins” in biopharma.

About minority research in clinical trials

Other Studies

https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.112.970202

From CRC Website

https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-spravato-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief-300807366.html

About Us

Founded in 2005 Apex Medical Research, AMR, Inc. is a multi-specialty dedicated research facility conducting phase I to phase IV clinical trials. Apex is in the business of testing a hypothesis while putting the patient’s health first. We are committed to developing products that make a difference for the people who need them, and we never compromise on ethics or quality.

Apex has a combined 50 years of clinical research experience and has conducted more than 250 clinical research trials... Read more!

Copyright © 2020. Apex Medical Research, Inc. , All rights reserved | By Axiom Elabs